Polaris Partners — Full Portfolio

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

Arnon Rosenthal(Ph.D.)Tillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in

BoardCarl Gordon(Director)

Board seatTerry McGuire· per SEC Form D · $32.3M raise · filed Sep 2015

Co-investorsForesite CapitalMission Bay CapitalMission BiocapitalMRL Ventures FundSV Health Investors

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Frederic Chereau(Executive Officer)

BoardAkkaraju Srinivas(Non-Management Director)

Board seatAmir Nashat· per SEC Form D · $76.3M raise · filed Apr 2015

Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesDomain PartnersSamsara BioCapital

BiotechCambridge, US

JOSH MANDEL-BREHM(Executive Officer, Director)RICHARD YOUNG(Director)

BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)in

Board seatAmir Nashat· per SEC Form D · filed Jun 2022

Co-investors5AM VenturesAndreessen HorowitzLongwood Fund

Cardlytics operates a commerce media platform that uses card-linked purchase data to deliver targeted offers and closed-loop measurement for marketers and advertisers, and personalized rewards programs for banks and publishers.

AdTechFintechMarketing TechAtlanta, US

Scott Grimes(Executive Officer, Director)inLynne Laube(Executive Officer, Director)Kirk Somers(Executive Officer)David Evans(Executive Officer)

BoardJohn Klinck(Director)inMark Johnson(Director)in

Board seatBryce Youngren· per SEC Form D · $11.9M raise · filed Jun 2017

Co-investorsBaroda VenturesCanaan PartnersKinetic Ventures, L.L.C.Next Coast VenturesSavano Capital PartnersHyperplane Venture Capital+1 more

Cartesian Therapeutics is a biotechnology company developing cell therapies, formed through the November 2023 merger with Selecta.

BiotechHealthtechWatertown, US

Metin Kurtoglu(Executive Officer)Chris Jewell(Executive Officer)Carsten Brunn(President, CEO & Chairman of the Board)inEmily English(Executive Officer)Blaine Davis(Executive Officer)Stephen Smolinksi(Executive Officer)

Board seatAmir Nashat· per SEC Form D · $70M raise · filed Jan 2020

Co-investorsK2 HealthVenturesMaryland TEDCOSchooner CapitalTEDCO

Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.

BiotechDigital HealthMental HealthCambridge, US

William Huyett(Executive Officer)Mark G. Currie(Executive Officer)Ole Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)George Conrades(Director)

Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $24.3M raise · filed Aug 2020

Co-investorsPappas Capital

Daré Bioscience is a women's health biotech company that conducts end-to-end clinical development of targeted therapeutics and products for conditions across areas such as contraception, menopause, vaginal infections, and sexual wellness.

BiotechDigital HealthFemTechSan Diego, US

MarDee Haring-Layton(Chief Accounting Officer)Sabrina Martucci Johnson(Founder & Chief Executive Officer)Christopher D.T. Guiffre(Executive Officer, Director)Gregg Beloff(Executive Officer)Alejandra V. Carvajal(Executive Officer)Adrian Senderowicz(Executive Officer)

Board seatAlan Crane· per SEC Form D · $1 raise · filed Oct 2016

Fate Therapeutics develops clinical-stage cell therapy drug candidates for autoimmune diseases and cancer, using an induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered cell products.

BiotechHealthtechSan Diego, US

Christian Weyer(Executive Officer, Director)J. Scott Wolchko(Executive Officer)Daniel Shoemaker(Executive Officer)

BoardJohn Mendlein(Director)William Rastetter(Director)

Board seatAmir Nashat· per SEC Form D · $10.3M raise · filed Aug 2016

Co-investorsSanofi VenturesVenrock

Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.

BiotechHealthtechMedical DevicesLexington, US

HARITH RAJAGOPALAN(Executive Officer, Director)JAY CAPLAN(Executive Officer, Director)Harith Rajagopalan(Executive Officer, Director)inLISA DAVIDSON(Executive Officer)Ajay Royan(Director)Christopher Gabrieli(Director)

Board seatAmy Schulman· per SEC Form D · $20.1M raise · filed Jan 2022

Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPMithril Capital ManagementVeltro Argento

Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.

BiotechDeep TechHealthtechMedical DevicesFramingham, US

Anand Varadan(Director)Richard Batycky(Director)Peter Ludlum(Interim CEO; Interim CFO)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)

BoardRichard Conley(Director)

Board seatTerrance McGuire· per SEC Form D · $3.7M raise · filed Dec 2018

Co-investors5AM VenturesARCH Venture Partners

Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)

BoardKristina Burow(Director)inKatrine Bosley(Director)Michael Gilman(Director)

Board seatAmir Nashat· per SEC Form D · $40M raise · filed Jan 2016

Co-investorsAisling CapitalARCH Venture PartnersEcoR1 Capital

Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Alan Buckler(Executive Officer)

Board seatAmir Nashat· per SEC Form D · $47M raise · filed Jan 2018

Co-investorsSamsara BioCapitalARCH Venture Partners

BiotechBoston, US

Omid Farokhzad(Director)Philip Ma(Executive Officer)Shadi Aryanpour(Executive Officer)David Singer(Director)

BoardRobert Langer(Director)

Board seatTerrance McGuire· per SEC Form D · $6M raise · filed Jan 2018

BiotechWatertown, US

Timothy Springer(Director)Andrew Kruse(Director)Timothy A. Springer(Director)Alise Reicin(Executive Officer, Director)Daniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)

Board seatTerry McGuire· per SEC Form D · $80.1M raise · filed Apr 2021

Co-investorsAlly Bridge GroupClarusEcoR1 CapitalSoleus CapitalVida Ventures

Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer.

BiotechHealthtechMedical DevicesRochester, US

Maurice Zauderer, Ph.D.(Director, Executive Officer)Maurice Zauderer(Executive Officer, Director)Elizabeth Evans(Executive Officer)Ernest S. Smith Ph.D.(Executive Officer)Jill Sanchez(Executive Officer)Ernest S. Smith(Executive Officer)

Board seatAlan Crane· per SEC Form D · $18.2M raise · filed Jul 2017

BiotechBoston, US

Mary DiBiase(Executive Officer)Christophe Arbet-Engels(Executive Officer)David Kirske(Executive Officer)John Volpone(Executive Officer)Mark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)

Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $50.5M raise · filed May 2017

Co-investorsOmega Funds

Leyden Labs develops nasal sprays that provide immediate protection against entire families of respiratory viruses through passive immunity, without relying on the body's own immune response.

BiotechHealthtechImpact & Social GoodMedical DevicesLeiden, NL

Koenraad Wiedhaup(Founder & CEO)inRonald Brus(Founder and Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)in

Co-investorsClavystBioInvest-NLQiming Venture PartnersConnecticut InnovationsF-Prime CapitalGV (Google Ventures)+1 more

Bedford, US

Franciscus J.A. van Mierlo(Executive Officer, Director)

BoardReidar Langmo(Director)Robert Metcalfe(Director)Carmichael Roberts(Director)Yasheng Huang(Director)Bruce Sohn(Director)

Board seatAmir Nashat· per SEC Form D · $30M raise · filed May 2016

Watertown, US

Maria Palasis(Director, Executive Officer)

BoardRobert Langer(Director)Guido Neels(Director)Richard Mott(Director)Carmichael S. Roberts(Director)

Board seatTerrance McGuire· per SEC Form D · $6M raise · filed Nov 2016

US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.

AgTechResearch Triangle Park, US

Scott Uknes(Manager)Eric Ward(Manager)Paul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)

BoardThomas Dietz(Manager)Kristina Burow(Manager)in

Board seatAmir Nashat· per SEC Form D · $117.2M raise · filed Feb 2022

Co-investorsAliment CapitalBlue Horizon CorporationPontifax AgTechARCH Venture PartnersNovalis LifeSciences

HealthtechWaltham, US

Tillman Gerngross(Executive Officer, Director)

Board seatAmy Schulman· per SEC Form D · $10M raise · filed Dec 2022

Co-investorsAtlas Venture

Ankyra Therapeutics is a biopharmaceutical company developing drugs, with a team that has collectively contributed to bringing seven drugs to global market approval.

BiotechDeep TechHealthtechMedical DevicesAustin, US

Tillman Gerngross(Executive Officer, Director)

Board seatTerrance McGuire· per SEC Form D · $14.5M raise · filed May 2020

Co-investorsGV (Google Ventures)Mithril Capital Management

Phoenix, US

Mark Verstegen(Executive Officer, Director)Dan Burns(Executive Officer, Director)Peter Hotz(Director)Timothy Kilgallon(Director)Rick Smith(Executive Officer)Jonathan Flint(Director)in

Board seatJonathan Flint· per SEC Form D · $193.8K raise · filed Feb 2016

Co-investorsABS Capital Partners

BiotechNewton, US

Katharine Yen(Executive Officer, Director)Kate Yen(Founder)inChristopher Guiffre(Executive Officer)

BoardAlon Lazarus(Director)Anna French(Director)

Board seatAlexandra Cantley· per SEC Form D · $42.3M raise · filed Dec 2025

Co-investorsDCVC (Data Collective)

Marblehead, US

Scott Cousino(Director)Ronald Geraty(Executive Officer, Director)

Board seatAlexandra Cantley· per SEC Form D · $8.2M raise · filed Nov 2022

BiotechPortland, US

Benjamin J. Shaw(Executive Officer, Director)

BoardEdward L. Cahill(Director)

Board seatTerrance G. McGuire· per SEC Form D · $14.5M raise · filed Apr 2021

ByHeart is an infant formula company navigating an FDA return-to-market process following a product outbreak investigation.

ConsumerDirect to ConsumerFoodTechHealthtechNew York, US

Mia B. Funt(Executive Officer, Director)Ron Belldegrun(Executive Officer, Director, Promoter)Mia Funt(Founder)inGeorg Krause-Vilmar(Executive Officer)Niall Mullane(Executive Officer)

Board seatAmy Schulman· per SEC Form D · $95.5M raise · filed May 2026

Co-investorsEvolution VC PartnersOCV PartnersRed Sea VenturesVida Ventures

BiotechBurlington, US

Michael Mendelsohn(Executive Officer, Director)

BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)inNicholas Downing(Director)

Board seatAmy Schulman· per SEC Form D · $17.5M raise · filed Dec 2022

Co-investorsBain Capital Life SciencesBain CapitalNEA SecondaryThird Rock Ventures

Cambridge, US

Ying Kai Chan(Executive Officer, Director, Promoter)Andrew Dick(Director, Promoter)

BoardKhoo Shih(Director)

Board seatAlexandra Cantley· per SEC Form D · $15.7M raise · filed Aug 2025

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in

BoardSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in

Board seatAlexandra Cantley· per SEC Form D · $80M raise · filed Sep 2025

Co-investorsMPM BioImpactPfizer Venture InvestmentsPfizer VenturesTaiho Ventures, LLC

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

Richard Young, Ph.D.(Director)Anthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)Ameet Nathwani, M.D.(Executive Officer, Director)

Board seatAmir Nashat· per SEC Form D · $150M raise · filed Feb 2022

Co-investorsARCH Venture PartnersEcoR1 CapitalSamsara BioCapital6 Dimensions CapitalGeneral CatalystInnovation Endeavors+5 more

On-demand alcohol delivery platform providing consumers with a better way to shop for wine and spirits

Sherborn, US

Justin Robinson(Executive Officer)inNicholas Rellas(Executive Officer, Director)James Cory Rellas(Executive Officer)

BoardWalt Doyle(Director)Barkley Stuart(Director)

Board seatPat Kinsel· per SEC Form D · $34.6M raise · filed Dec 2018

Co-investorsAvenir Growth CapitalEdmonton UnlimitedWinklevoss CapitalAvenirSuffolk Equity PartnersTiger Global Management

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSamuel Bjork(Director)Seiji Miyahara(Director)

Board seatAlexandra Cantley· per SEC Form D · $73M raise · filed Apr 2024

Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapital+3 more

Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.

BiotechSeattle, US

Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)

BoardPaulina Hill(Director)Steven Gillis(Executive Officer, Director, Promoter)in

Board seatTerrance McGuire· per SEC Form D · $102.8M raise · filed Nov 2022

Co-investorsARCH Venture PartnersOUP (Osage University Partners)

Philadelphia, US

Gabriel Otte(Executive Officer, Director)

BoardCharles Roberts(Director)

Board seatAmir Nashat· per SEC Form D · $270M raise · filed Aug 2020

Co-investorsAndreessen HorowitzRA Capital

BiotechCambridge, US

Gabriel Kwong(Executive Officer)Sirshendu Roopom Banerjee(Executive Officer)

BoardTheresia Guow(Director)Stan Lapidus(Director)

Board seatAmy Schulman· per SEC Form D · $18M raise · filed Dec 2021

Co-investorsGreatPoint VenturesAcrew CapitalAspect VenturesCatalio Capital ManagementDns CapitalNew Leaf Venture Partners+2 more

New York, US

Mark Alexander(Executive Officer, Director)Anthony Sciortino(Executive Officer)John Heath(Executive Officer)Brant Wutzl(Executive Officer)Gregg Rubin(Executive Officer, Director)

BoardHallbjorn Karlsson(Director)

Board seatTerrance McGuire· per SEC Form D · $9.1M raise · filed Jan 2017

Iora Health was a primary care company focused on value-based care for Medicare-eligible seniors, operating clinics with a team-based model including health coaches.

Digital HealthHealthtechWellness & FitnessSan Francisco, US

RUSHIKA FERNANDOPULLE(Executive Officer, Director)CHRISTOPHER J. MCKOWN(Executive Officer, Director)DAVID FIELDING(Executive Officer)ALEXANDER PACKARD(Executive Officer)DAVID JUDGE(Executive Officer)

BoardSTEPHEN KNIGHT(Director)in

Board seatTerry McGuire· per SEC Form D · $48.2M raise · filed Sep 2015

Co-investors.406 VenturesDag VenturesF-Prime CapitalFlare Capital PartnersGV (Google Ventures)Lifeforce Capital+5 more

Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.

BiotechDigital HealthHealthtechCambridge, US

PETER M. HECHT(Executive Officer, Director)MARK G. CURRIE(Executive Officer)HALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)THOMAS A. MCCOURT(Executive Officer)

Board seatTerrance G. Mcguire· per SEC Form D · $150M raise · filed Oct 2016

Co-investorsF-Prime CapitalMountain Group CapitalRidgeback CapitalVenrockMaverick Ventures

Boston, US

Board seatTerrance G. McGuire· per SEC Form D · $50M raise · filed Aug 2021

Co-investorsVersant Ventures

Kallyope is a drug discovery and development company working on therapeutic agents for neurological and metabolic diseases.

BiotechDeep TechHealthtechMedical DevicesNew York City, US

Tom Maniatis(Director)Nancy Thornberry(Executive Officer, Director)Kenneth Clark(Executive Officer)

BoardJoshua Wolfe(Director)inTim Kutzkey(Director)

Board seatTerry McGuire· per SEC Form D · $44M raise · filed Oct 2016

Co-investorsDns CapitalIllumina VenturesLux CapitalThe Column Group

BiotechWatertown, US

Carlo Giovanni Traverso(Director)Amy W. Schulman(Executive Officer, Director)inRobert S. Langer(Director)

BoardZafi Avnur(Director)Edmund Harrigan(Director)Catherine Reynolds(Director)

Board seatAmy Schulman· per SEC Form D · $206.1M raise · filed Dec 2023

Co-investorsBill & Melinda Gates FoundationKendall Capital Partners

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKristina Burow(Director)inRichard Heyman(Director)in

Board seatAmir Nashat· per SEC Form D · $37.8M raise · filed Nov 2016

Co-investorsage1EcoR1 CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+2 more

HealthtechLexington, US

Robert S. Langer(Director)Michael J. Cima(Director)David Neafus(Executive Officer)Cheryl R. Blanchard(Executive Officer, Director)Robert Farra(Executive Officer)

Board seatTerrance G. McGuire· per SEC Form D · $18.6M raise · filed Jun 2015

Co-investorsKendall Capital Partners

BiotechWaltham, US

Timothy Springer(Director)Praveen Tiprirneni(Executive Officer, Director)Robert Farrell(Executive Officer)

BoardBarbara Dalton(Director)Ramy Farid(Director)Kevin Bitterman(Director)in

Board seatAmir Nashat· per SEC Form D · $100M raise · filed Mar 2023

Co-investorsAtlas VentureOmega Funds

BiotechCambridge, US

Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)George Vlasuk(Executive Officer, Director)

BoardJean-Francois Formela(Director)inMarian Nakada(Director)

Board seatAlan Crane· per SEC Form D · $25M raise · filed Mar 2018

Co-investorsage1Brace PharmaSanofi VenturesAtlas VentureSR One Capital Management

Noetik builds AI models to identify cancer patients most likely to respond to treatments and to discover new oncology drug targets.

AI & Machine LearningBiotechHealthtechSouth San Francisco, US

Jacob Rinaldi(Executive Officer, Director, Promoter)Ronald Alfa(Executive Officer, Director, Promoter)Ron Alfa, MD, PhD(Founder)in

BoardJames Hardiman(Director)in

Board seatAmy Schulman· per SEC Form D · $40M raise · filed Aug 2024

Co-investors11.2 CapitalBreakout VenturesLinearis VenturesNorth South VenturesDCVC (Data Collective)

Nomad Health operates a self-service digital marketplace connecting clinicians—including doctors, nurses, and allied health professionals—with healthcare facilities for staffing and travel assignments without traditional recruiters.

B2B MarketplacesDigital HealthHealthtechHR TechMarketplacesNew York, US

Alexander Nazem(Director)inMaxwell Laurans(Director)Alexi Nazem(Co-Founder & Board Member)Justin Lambert(CEO)William Eager(Vice President of Engineering)Alexander Pease(Vice President of Product)

Board seatBrian Chee· per SEC Form D

Co-investorsAlleyCorpIcon Ventures.406 VenturesAdams Street PartnersFirst Round CapitalHealthQuest Capital+1 more

BiotechCambridge, US

Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)Anthony Coyle(Executive Officer, Director)Christopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)

Board seatAlan Crane· per SEC Form D · $80M raise · filed Apr 2020

Co-investorsAccess BiotechnologyVersant Ventures

Podimetrics offers a virtual care service that combines remote foot monitoring with personalized support to help people with complex diabetes prevent foot complications such as amputations.

Digital HealthHealthtechMedical DevicesSomerville, US

David Linders(Executive Officer, Director)Jonathan Bloom(Executive Officer, Director)

BoardAaron Sandoski(Director)in

Board seatAlexandra Cantley· per SEC Form D · $60M raise · filed Apr 2022

Co-investorsNorwich VenturesScientific Health DevelopmentSV Health InvestorsRock Health

Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.

BiotechHealthtechCarlsbad, US

Board seatAmir Nashat· per SEC Form D · $24M raise · filed Nov 2020

Co-investorsBioBritBioRock VenturesSamsara BioCapital

BiotechLexington, US

Robert Clarke(Chief Executive Officer and Member of the Board of Directors)David Hava(Chief Scientific Officer)David Edwards(Director)

BoardSteven Gillis(Director)David Maki(Director)

Board seatTerrance McGuire· per SEC Form D · $34.1M raise · filed Jun 2015

Co-investors5AM Ventures

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)Shafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)

Board seatAmy Schulman· per SEC Form D · $24.9M raise · filed Sep 2025

Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health Investors+2 more

Seismic Therapeutic is a clinical-stage biotechnology company that uses machine learning to discover and develop immunology therapies for autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesBoston, US

JoTimothy A. Springer(Scientific Advisor / Founder)Kevin(Head of Immunology and Biomarker)Jo Viney, PhD(Founder, President and Chief Executive Officer)Alan Crane(Founder and Chairman of Seismic Therapeutic; Polaris Partners)Tim Springer, PhD(Founder of Seismic Therapeutic; Harvard Medical School and Boston Children's Hospital)

Board seatAlan Crane· per SEC Form D · $146.3M raise · filed Sep 2024

Co-investorsBessemer Venture PartnersGV (Google Ventures)Mana Ventures

Minneapolis, US

Sara Taylor(Executive Officer)Mike Christy(Executive Officer)Gregory Johnson(Executive Officer)Ken Ehlert(Executive Officer, Director)Mark Briesacher(Executive Officer)Mark Pollmann(Executive Officer)

Board seatAmy Schulman· per SEC Form D · $1.5M raise · filed Nov 2025

BiotechCambridge, US

HOWARD BERNSTEIN(Executive Officer)HOWARD WEISMAN(Executive Officer, Director)

BoardROBERT LANGER(Director)ANUPENDRA SHARMA(Director)HARRY WILCOX(Director)

Board seatAlan Crane· per SEC Form D · $10M raise · filed Sep 2017

Sofregen develops medical biomaterials based on purified silk protein for soft tissue regeneration, including injectable fillers and applications such as vocal fold medialization.

BiotechHealthtechMedical DevicesCambridge, US

Milan Kofol(Executive Officer)Doug Sheldon(Director)Anh Hoang(Executive Officer)Howard Weisman(Executive Officer, Director)

Board seatAmir Nashat· per SEC Form D · $9.7M raise · filed Sep 2017

Co-investorsAnzu Partners

Cambridge, US

Board seatAlexandra Cantley· per SEC Form D · $23.2M raise · filed May 2023

Cambridge, MA gene-control biopharma that developed tamibarotene for RARA-overexpressing blood cancers; now in wind-down.

Cambridge, US

Board seatAmir Nashat· per SEC Form D · $121.6M raise · filed Dec 2020

Co-investorsARCH Venture PartnersSamsara BioCapital

BiotechSouth San Francisco, US

M. Johnston Erwin Jr.(Executive Officer, Director)

BoardEric Pham(Director)Travis Coy(Director)Carol Gallagher(Director)Joel Marcus(Director)Michael Ross(Director)

Board seatAlexandra Cantley· per SEC Form D · $85M raise · filed Nov 2024

BiotechWaltham, US

Garry Nicholson(Executive Officer, Director)Edward Freedman(Executive Officer)Rakesh Jain(Director)

BoardRobert Langer(Director)David Mott(Director)

Board seatAlan Crane· per SEC Form D · $22M raise · filed Sep 2016

Co-investorsCTI Life Sciences Fund L.P.

Allstacks is an AI-agent platform that connects data from software development tools (Jira, GitHub, GitLab, Jenkins) to provide engineering teams and leaders with delivery metrics, risk alerts, and recommendations for planning, managing, and optimizing software creation.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareRaleigh, US

Jeremy Freeman(Founder)Hersh A. Tapadia(Executive Officer, Director)Hersh Tapadia(Founder)inDarrell J. Freeman, Jr.(Executive Officer, Director)Scot Sherwood(Director)

BoardAndrew Drylie(Director)in

Co-investorsAtlassian VenturesCompanyon VenturesCreativeCoFirst Rays Venture PartnersGutbrain VenturesHyperplane Venture Capital+7 more

Baxter Planning provides software and services for service supply chain management, serving enterprises managing complex operational logistics and supplier networks.

AI & Machine LearningEnterprise SoftwareLogistics & Supply ChainSaaS

Anton Chilton(Chief Executive Officer)in

Co-investorsGolub GrowthMarlin Equity Partners

Sitecore provides a content management and customer experience platform that uses AI to help brands manage content, data, and personalized digital experiences across multiple channels.

AI & Machine LearningEnterprise SoftwareMarketing Tech

Co-investorsFrontline VenturesTola Capital

Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases.

AI & Machine LearningBiotechWatertown, US

Eric Kelsic(CEO & Cofounder)inSam Sinai(Vice President, Head of ML & Cofounder)inAdrian Veres(Chief Scientific Officer & Cofounder)George Church(Scientific Cofounder)Tomas Bjorklund(Scientific Co-founder)Alan Crane(Executive Chairman & Cofounder, Polaris Entrepreneur Partner)

Co-investorsAndreessen HorowitzCRV (Charles River Ventures)GENERAL INCEPTIONGV (Google Ventures)Lux CapitalObvious Ventures+2 more

Egnyte provides software for protecting and managing business-critical content across organizations of all sizes.

AI & Machine LearningCloud ComputingCybersecurityEnterprise Software

Vineet Jain(Chief Executive Officer)inAmrit Jassal(Founder)in

Co-investorsGI PartnersTA AssociatesFloodgateGolub GrowthW Capital PartnersGV (Google Ventures)+1 more

FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.

Digital HealthHealthtechBoston, US

A.G. Breitenstein(Founder)inLena Ballantine(Executive Officer)Liana M Guzman Weis(Executive Officer, Director)

BoardLynne Chou O'Keefe(Director)inMorgan Cheatham(Director)inLee Shapiro(Director)in

Co-investors7wire VenturesBessemer Venture PartnersCorewell Health VenturesDefine VenturesHabitat PartnersSeae Ventures+2 more

AI & Machine LearningEnterprise SoftwareHR TechSaaSNew York, US

Nilanjana Bhowmik(Director)Ross Goldstein(Director)Peter Flint(Director)R. Douglas Higgins(Director)Joe Essenfeld(Executive Officer, Director)Jim Baum(Director)

Co-investorsConvergeMontage CapitalRunway Growth CapitalSapphire VenturesDFJGotham Ventures+1 more

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)FRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)

BoardALAN L. CRANE(Director)

Co-investorsAlpha Wave GlobalARCH Venture PartnersLAVLilly Asia VenturesBaillie GiffordFlagship Pioneering

Lob provides software and hardware infrastructure for automating, personalizing, and tracking direct mail campaigns at scale.

Enterprise SoftwareLogistics & Supply ChainMarketing TechSaaSNew York City, US

Eduardo Browne(Executive Officer)Donnell Vanker(Executive Officer)Harry Zhang(Founder)Leore Avidar(Founder)

Co-investorsFloodgateFrontline VenturesStructural CapitalTodd and Rahul’s Angel FundY CombinatorFirst Round Capital+3 more

Localytics is an AI implementation firm that builds, integrates, and operates marketing AI systems for enterprise consumer brands.

AI & Machine LearningEnterprise SoftwareMarketing TechSaaSBoston, US

John Dobrowolski(CEO)inDerick Thompson(VP of Operations)inJuan Yrigoyen(Head of Product)inJoey Rahman(Head of Engineering)Carl Jones(CTO)

Co-investorsBantam GroupLaunchCapitalMI VenturesSapphire VenturesTechstarsFoundation Capital

AI & Machine LearningCloud ComputingCybersecurityData & InfrastructureEnterprise Software

Co-investorsFrontline VenturesFloodgate

Matter develops a consumer iOS app that helps users track positive emotions and brain activity to improve subjective well-being.

AI & Machine LearningConsumerHealthtechMental HealthWellness & Fitness

Axel Bouchon(Founder)Ben Goldhirsh(Co-founder)Chris Shiflett(Co-founder)

Co-investorsARCH Venture PartnersCollaborative FundExor Ventures

Qstream is an enterprise microlearning and knowledge reinforcement platform built on neuroscience algorithms, delivering personalized, spaced learning along with analytics on knowledge retention and job performance readiness.

AI & Machine LearningEdTechEnterprise SoftwareHR TechSaaSBurlington, US

Duncan Lennox(Executive Officer, Director, Promoter)Branch Price Kerfoot(Director)

BoardHambleton Lord(Director)inShay Garvey(Director)inGaye Bok(Director)Harold Copperman(Director)

Co-investorsDelta PartnersExcel Venture ManagementLaunchpad Venture GroupEnterprise IrelandBantam GroupFrontline Ventures